N/A Completed N=75 Randomized Triple-blind Treatment

Use of Insulin Glargine to Treat Diabetic Ketoacidosis

Diabetic Ketoacidosis

Source: ClinicalTrials.gov NCT00179127 ↗

Enrolled (actual)

Serious AEs

—

Results posted

Jul 2018

Primary outcomePrimary: Time of Acidosis Correction

Summary

The purpose of this study is to determine the effects of the addition of insulin glargine during the early phase of moderate to severe Diabetic Ketoacidosis (DKA) in children. The investigators hypothesize that the addition of insulin glargine during the early phase of management of DKA will accelerate acidosis correction, decrease the length of insulin infusion, and decrease the total intensive care unit time in children admitted to the ICU.

Outcome Measures

Outcome	Result	p-value
PRIMARY Time of Acidosis Correction	—	—
SECONDARY Time on Insulin Drip	—	—
SECONDARY Total Hospital Stay	—	—

Eligibility Criteria

Inclusion Criteria

Ages 6-18 y.o. presenting to Vanderbilt Children's Hospital (VCH) Emergency Room with:
Established history of insulin dependent diabetes

AND:

Chief c/o hyperglycemia or vomiting
Venous pH 150
Urinary Ketones

Exclusion Criteria

Age 7.24
Serum Bicarbonate > 18
Pregnancy
Received glargine within 12 hours prior to arrival to VCH Emergency Room/Pediatric Critical Care Unit

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00179127). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.